Search
Search Results
-
Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells
Myelodysplastic neoplasms (MDS) encompass haematological malignancies, which are characterised by dysplasia, ineffective haematopoiesis and the risk...
-
Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease
Whilst it is recognised that targeting self-renewal is an effective way to functionally impair the quiescent leukaemic stem cells (LSC) that persist...
-
PD-1 signalling defines and protects leukaemic stem cells from T cell receptor-induced cell death in T cell acute lymphoblastic leukaemia
T cell acute lymphoblastic leukaemia (T-ALL) is an aggressive malignancy with poor prognosis, but a decisive marker and effective treatment for...
-
Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions
BackgroundSeveral studies have described a potential anti-tumour effect of cannabinoids (CNB). CNB receptor 2 (CB2) is mostly present in...
-
FANCA deficiency promotes leukaemic progression by allowing the emergence of cells carrying oncogenic driver mutations
Leukaemia is caused by the clonal evolution of a cell that accumulates mutations/genomic rearrangements, allowing unrestrained cell growth. However,...
-
Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells
Deregulated oxidative metabolism is a hallmark of leukaemia. While tyrosine kinase inhibitors (TKIs) such as imatinib have increased survival of...
-
VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells
Haematopoietic stem cells (HSCs) home to the bone marrow via, in part, interactions with vascular cell adhesion molecule-1 (VCAM1)
1 –3 . Once in the...
-
-
Cancer Stem Cell Markers in Haematological Malignancies
Cancer stem cells (CSCs) are a subgroup of tumour cells with tumorigenic potential due to their ability to transform into tumours through...
-
Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells
Therapeutic genome editing of haematopoietic stem cells (HSCs) would provide long-lasting treatments for multiple diseases. However, the in vivo...
-
The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness
Mitochondrial metabolites regulate leukaemic and normal stem cells by affecting epigenetic marks. How mitochondrial enzymes localize to the nucleus...
-
Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome
Transfer RNA-derived fragments (tRFs) are emerging small noncoding RNAs that, although commonly altered in cancer, have poorly defined roles in...
-
Detection and Isolation of Cancer Stem Cells
The discovery and isolation of the hematopoietic stem cell (HSC) from bone marrow grafts introduced the concept of a cell type capable of restoring...
-
Nanomedicine Targeting Cancer Stem Cells
Cancer stem cells (CSCs) constitute a subset of cells endowed with the remarkable abilities of self-renewal, proliferation, and differentiation....
-
Frontline Management of Acute Myeloid Leukaemia Eligible for Intensive Chemotherapy
The phrase ‘Panta Rhei—everything flows’ by the Greek philosopher Heraclitus, a purported reference to a constantly changing flowing river, or more...
-
Cancer incidence in healthy Swedish peripheral blood stem cell donors
Granulocyte colony-stimulating factor (G-CSF) has been used for over 20 years to obtain peripheral blood stem cells from healthy donors for...
-
Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC
We report the results from a multicentre retrospective study of 220 adult patients who underwent allogeneic hematopoietic stem cell transplantation...
-
Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation
We report the results of a Phase I radiation dose escalation study using an yttrium-90 ( 90 Y) labelled anti-CD66 monoclonal antibody given with...
-
Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis
Mutations in a diverse set of driver genes increase the fitness of haematopoietic stem cells (HSCs), leading to clonal haematopoiesis
1 . These lesions...
-
